Cholangiocarcinoma News

Genetic Classification of iCCA Can Have Significant Prognostic Value

March 2023, Vol 4, No 1

The clinical heterogeneity of intrahepatic cholangiocarcinoma (iCCA) may be a result of multiple cells of origin and variable driver gene alterations; however, certain features are shared with hepatocellular carcinoma (HCC) and extrahepatic CCA (eCCA). A statistical algorithm, the hidden-genome classifier, classifies tumors by identifying tumor genetic origin and integrating multilevel metagenetic information. Dr Yi Song presented results from a retrospective review using the hidden-genome classifier to quantify the genetic heterogeneity of iCCA with a view toward improved tumor classification. Investigators trained and internally validated the hidden-genome classifier using eCCA, gallbladder cancer (GBC), and HCC as extremes on the spectrum.

A retrospective review of patients with biopsy-confirmed iCCA, eCCA, GBC, and HCC was conducted, and a total of 1264 patients were analyzed, 527 with iCCA, 206 with eCCA, 233 with GBC, and 298 with HCC. The iCCA tumors demonstrated a continuous spectrum of alterations similar to eCCA and HCC, ranging from biliary class (122 tumors) to intermediate class (375 tumors) to HCC class (30 tumors).

In patients with unresected iCCA, the median survival ranged from 1 year in the biliary class to 1.8 years in the intermediate class to 2.3 years in the HCC class. In patients who underwent resection, the median survival was 2.4 years in the biliary class, which was lower than both the intermediate class (5.1 years) and the HCC class (4.9 years; Table).

Song Y, et al. Genetic heterogeneity of intrahepatic cholangiocarcinoma: implication for outcome. Poster presented at: ASCO Gastrointestinal Cancer Symposium meeting: January 19-23; San Francisco, CA.

Overall, iCCAs are heterogeneous tumors with a spectrum of genetic alterations with some similarities to HCC and eCCA. Classification of genetic heterogeneity in iCCA may have significant prognostic value.

Source: Song Y, Boerner T, Drill E, et al. Genetic heterogeneity of intrahepatic cholangiocarcinoma: implication for outcome. Poster presented at: ASCO Gastrointestinal Cancers Symposium, January 19-21, 2023; San Francisco, CA. Abstract 595.

Related Items

Characterization of Long-Term Survivors in TOPAZ-1
March 2023, Vol 4, No 1
Researchers examined the characteristics, outcomes, and genomic profiles of patients with advanced biliary tract cancer who were treated with durvalumab plus gemcitabine/cisplatin and experienced long-term survival.
MDM2-p53 Antagonist BI 907828 Demonstrated Promising Activity in Patients with Advanced BTC
March 2023, Vol 4, No 1
The novel MDM2-p53 antagonist BI 907828 is being investigated as a first-line treatment in patients with advanced biliary tract cancer.
Treatment and Survival Outcomes with Systemic Therapy for Patients with BTC with IDH1 Mutations: A Retrospective Study
March 2023, Vol 4, No 1
Long-term outcomes were evaluated in patients with IDH1-mutated biliary tract cancer who were treated with systemic therapy.
Phase 2 Study of CTX-009 plus Paclitaxel in Patients with Advanced BTC
March 2023, Vol 4, No 1
CTX-009 plus paclitaxel showed promising efficacy as second- or third-line treatment in patients with advanced biliary tract cancer.
Gunagratinib in Patients with Previously Treated Advanced CCA Harboring FGFR2 Fusions or Rearrangements
March 2023, Vol 4, No 1
Gunagratinib showed promising efficacy as a second-generation FGFR inhibitor and demonstrated potential to treat multiple FGFR pathway abnormalities.
Results from SWOG 1815: GemCis and Nab-Paclitaxel versus GemCis in Advanced BTC
March 2023, Vol 4, No 1
The SWOG 1815 trial found that treatment with gemcitabine/cisplatin and paclitaxel (GAP) did not result in a significant improvement in survival compared with gemcitabine and cisplatin in patients with advanced biliary tract cancer, though GAP may be beneficial in patients with locally advanced disease and GBC.
JCOG1202 Subgroup Analysis: Risk Factors for Early Relapse in Patients Undergoing Curative Resection
March 2023, Vol 4, No 1
A study of patients with resected biliary tract cancer (BTC) found that postoperative CA 19-9 level, tumor differentiation, lymph node metastases, and residual tumor significantly impact early relapse in patients with curatively resected BTC. Similar risk factors were also found in patients receiving adjuvant S-1.
Impact of Gene Expression in 5-FU Metabolic Pathways on Outcomes in Patients Enrolled in JCOG1202
March 2023, Vol 4, No 1
Results from a study evaluating the impact of 5-FU metabolic pathway enzyme expression on outcomes of patients with curatively resected biliary tract cancer showed that relapse-free survival was improved in patients with certain enzymes who received adjuvant S-1.
Atezolizumab with or without Bevacizumab in Combination with GemCis in Advanced BTC: Results from IMbrave 151
March 2023, Vol 4, No 1
Researchers assessed whether VEGF blockade plus chemotherapy with gemcitabine/cisplatin can enhance responses to PD-L1 inhibition by promoting an immune-permissive tumor microenvironment in patients with advanced biliary tract cancer.
Nab-Paclitaxel plus Sintilimab as Second-Line Treatment for Advanced BTC
March 2023, Vol 4, No 1
The safety and efficacy of second-line nab-paclitaxel combined with the anti-PD-1 antibody sintilimab was studied in patients with advanced biliary tract cancer.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: